Correlation Between Innovent Biologics and Zentalis Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Innovent Biologics and Zentalis Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Innovent Biologics and Zentalis Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Innovent Biologics and Zentalis Pharmaceuticals Llc, you can compare the effects of market volatilities on Innovent Biologics and Zentalis Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Innovent Biologics with a short position of Zentalis Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Innovent Biologics and Zentalis Pharmaceuticals.

Diversification Opportunities for Innovent Biologics and Zentalis Pharmaceuticals

0.03

Correlation Coefficient

Innovent Biologics  Zentalis Pharmaceuticals

Significant diversification

The 3 months correlation between Innovent and Zentalis is 0.03. Overlapping area represents the amount of risk that can be diversified away by holding Innovent Biologics and Zentalis Pharmaceuticals Llc in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Zentalis Pharmaceuticals and Innovent Biologics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Innovent Biologics are associated (or correlated) with Zentalis Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Zentalis Pharmaceuticals has no effect on the direction of Innovent Biologics i.e., Innovent Biologics and Zentalis Pharmaceuticals go up and down completely randomly.

Pair Corralation between Innovent Biologics and Zentalis Pharmaceuticals

Assuming the 90 days horizon Innovent Biologics is expected to under-perform the Zentalis Pharmaceuticals. But the pink sheet apears to be less risky and, when comparing its historical volatility, Innovent Biologics is 1.69 times less risky than Zentalis Pharmaceuticals. The pink sheet trades about -0.14 of its potential returns per unit of risk. The Zentalis Pharmaceuticals Llc is currently generating about -0.05 of returns per unit of risk over similar time horizon. If you would invest  312.00  in Zentalis Pharmaceuticals Llc on October 22, 2024 and sell it today you would lose (88.00) from holding Zentalis Pharmaceuticals Llc or give up 28.21% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	96.88%
Values	Daily Returns

Innovent Biologics  vs.  Zentalis Pharmaceuticals Llc

Innovent Biologics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Innovent Biologics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders.

Zentalis Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Zentalis Pharmaceuticals Llc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in February 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Pair Trading with Innovent Biologics and Zentalis Pharmaceuticals

The main advantage of trading using opposite Innovent Biologics and Zentalis Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Innovent Biologics position performs unexpectedly, Zentalis Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zentalis Pharmaceuticals will offset losses from the drop in Zentalis Pharmaceuticals' long position.

The idea behind Innovent Biologics and Zentalis Pharmaceuticals Llc pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.